CD19 and diffuse large B-cell lymphoma: We therefore generated CD19-CAR T cells in the presence of 25 μM MITO-66 from peripheral blood of a heterogeneous cohort of patients, mainly aged diffuse large B cell lymphoma patients with various treatment histories (Table S1).